David Amsellem
Stock Analyst at Piper Sandler
(4.84)
# 110
Out of 5,241 analysts
182
Total ratings
68.03%
Success rate
23.3%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Reiterates: Overweight | $214 → $225 | $190.56 | +18.07% | 6 | May 15, 2026 | |
| AMGN Amgen | Maintains: Overweight | $432 → $427 | $330.75 | +29.10% | 8 | May 14, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $294 → $298 | $213.76 | +39.41% | 6 | May 14, 2026 | |
| AMPH Amphastar Pharmaceuticals | Reiterates: Neutral | $25 → $21 | $17.82 | +17.85% | 10 | May 11, 2026 | |
| DFTX Definium Therapeutics | Maintains: Overweight | $49 → $48 | $20.02 | +139.76% | 2 | May 8, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $190 → $207 | $154.36 | +34.10% | 13 | May 6, 2026 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $73 → $88 | $58.22 | +51.15% | 9 | May 1, 2026 | |
| TEVA Teva Pharmaceutical Industries | Reiterates: Overweight | $41 → $42 | $34.07 | +23.28% | 13 | Apr 30, 2026 | |
| OGN Organon & Co. | Upgrades: Neutral | $5 → $14 | $13.42 | +4.32% | 7 | Apr 28, 2026 | |
| ALKS Alkermes | Maintains: Overweight | $45 → $43 | $37.00 | +16.22% | 9 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $219 → $232 | $237.45 | -2.30% | 16 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $48 | $27.00 | +77.78% | 1 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $75 | $58.31 | +28.62% | 3 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $12 | $16.17 | -25.79% | 8 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $148 → $223 | $226.67 | -1.62% | 4 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $9.76 | +84.43% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $3.13 | +187.54% | 1 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $8 | $4.09 | +95.60% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $8 | $5.92 | +35.14% | 6 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 → $13 | $11.81 | +10.08% | 5 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $65 | $47.62 | +36.50% | 17 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $33.62 | +10.05% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $9 | $9.60 | -6.25% | 3 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $80.32 | -15.34% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $5.32 | -43.61% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $22.31 | +88.26% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $3.67 | +472.21% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $30.44 | +37.98% | 3 | Oct 16, 2023 |
Biogen
May 15, 2026
Reiterates: Overweight
Price Target: $214 → $225
Current: $190.56
Upside: +18.07%
Amgen
May 14, 2026
Maintains: Overweight
Price Target: $432 → $427
Current: $330.75
Upside: +29.10%
AbbVie
May 14, 2026
Maintains: Overweight
Price Target: $294 → $298
Current: $213.76
Upside: +39.41%
Amphastar Pharmaceuticals
May 11, 2026
Reiterates: Neutral
Price Target: $25 → $21
Current: $17.82
Upside: +17.85%
Definium Therapeutics
May 8, 2026
Maintains: Overweight
Price Target: $49 → $48
Current: $20.02
Upside: +139.76%
Neurocrine Biosciences
May 6, 2026
Maintains: Overweight
Price Target: $190 → $207
Current: $154.36
Upside: +34.10%
Corcept Therapeutics
May 1, 2026
Maintains: Overweight
Price Target: $73 → $88
Current: $58.22
Upside: +51.15%
Teva Pharmaceutical Industries
Apr 30, 2026
Reiterates: Overweight
Price Target: $41 → $42
Current: $34.07
Upside: +23.28%
Organon & Co.
Apr 28, 2026
Upgrades: Neutral
Price Target: $5 → $14
Current: $13.42
Upside: +4.32%
Alkermes
Mar 24, 2026
Maintains: Overweight
Price Target: $45 → $43
Current: $37.00
Upside: +16.22%
Mar 19, 2026
Maintains: Overweight
Price Target: $219 → $232
Current: $237.45
Upside: -2.30%
Feb 27, 2026
Initiates: Overweight
Price Target: $48
Current: $27.00
Upside: +77.78%
Feb 23, 2026
Maintains: Overweight
Price Target: $66 → $75
Current: $58.31
Upside: +28.62%
Jan 28, 2026
Maintains: Neutral
Price Target: $9 → $12
Current: $16.17
Upside: -25.79%
Jan 16, 2026
Maintains: Overweight
Price Target: $148 → $223
Current: $226.67
Upside: -1.62%
Jan 9, 2026
Initiates: Overweight
Price Target: $18
Current: $9.76
Upside: +84.43%
Nov 25, 2025
Initiates: Overweight
Price Target: $9
Current: $3.13
Upside: +187.54%
Nov 7, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $4.09
Upside: +95.60%
Nov 7, 2025
Maintains: Neutral
Price Target: $6 → $8
Current: $5.92
Upside: +35.14%
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $11.81
Upside: +10.08%
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $47.62
Upside: +36.50%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $33.62
Upside: +10.05%
Mar 21, 2025
Downgrades: Neutral
Price Target: $15 → $9
Current: $9.60
Upside: -6.25%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $80.32
Upside: -15.34%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $5.32
Upside: -43.61%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $22.31
Upside: +88.26%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $3.67
Upside: +472.21%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $30.44
Upside: +37.98%